Insider Selling: LifeStance Health Group (NASDAQ:LFST) Director Sells $9,059,633.81 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 894,337 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the transaction, the director owned 539,763 shares of the company’s stock, valued at $5,467,799.19. This represents a 62.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Robert Bessler also recently made the following trade(s):

• On Tuesday, May 12th, Robert Bessler sold 575,034 shares of LifeStance Health Group stock. The shares were sold at an average price of $8.02, for a total transaction of $4,611,772.68.
• On Thursday, May 7th, Robert Bessler sold 75,000 shares of LifeStance Health Group stock. The stock was sold at an average price of $8.55, for a total value of $641,250.00.
• On Friday, April 24th, Robert Bessler sold 62,147 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.05, for a total transaction of $438,136.35.
• On Thursday, April 23rd, Robert Bessler sold 7,752 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total value of $54,264.00.
• On Tuesday, April 21st, Robert Bessler sold 5,101 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total transaction of $35,758.01.

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $11.27 on Friday. The business has a 50 day simple moving average of $8.24 and a two-hundred day simple moving average of $7.37. LifeStance Health Group, Inc. has a 1-year low of $3.74 and a 1-year high of $11.62. The stock has a market capitalization of $4.37 billion, a PE ratio of 187.83 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.48 and a quick ratio of 1.48.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.The business had revenue of $403.48 million for the quarter, compared to the consensus estimate of $387.46 million. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, research analysts predict that LifeStance Health Group, Inc. will post 0.12 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LFST. BTIG Research increased their price objective on shares of LifeStance Health Group from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wall Street Zen cut LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 13th. Jefferies Financial Group raised LifeStance Health Group to a “strong-buy” rating in a research note on Thursday, March 12th. The Goldman Sachs Group started coverage on LifeStance Health Group in a report on Friday, June 5th. They set a “neutral” rating and a $9.00 target price for the company. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of LifeStance Health Group in a research note on Wednesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, LifeStance Health Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.75.

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently made changes to their positions in LFST. Assetmark Inc. lifted its position in shares of LifeStance Health Group by 17.0% during the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after acquiring an additional 1,367 shares during the period. Park Edge Advisors LLC lifted its holdings in LifeStance Health Group by 14.4% in the fourth quarter. Park Edge Advisors LLC now owns 11,863 shares of the company’s stock valued at $84,000 after buying an additional 1,495 shares during the period. California State Teachers Retirement System boosted its holdings in shares of LifeStance Health Group by 1.6% during the 4th quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock worth $885,000 after buying an additional 1,966 shares in the last quarter. Vident Advisory LLC boosted its position in shares of LifeStance Health Group by 12.7% during the 2nd quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock worth $112,000 after purchasing an additional 2,447 shares in the last quarter. Finally, Xponance LLC grew its position in LifeStance Health Group by 26.4% in the 4th quarter. Xponance LLC now owns 13,144 shares of the company’s stock valued at $93,000 after purchasing an additional 2,745 shares during the period. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.